A carregar...
Pegylated liposomal doxorubicin for myeloid neoplasms
Pegylated liposomal doxorubicin (Peg-Dox) treatment resulted in a good outcome for patients with lymphoma and multiple myeloma, with reduced cardiotoxicity and an improved pharmacokinetic profile when compared to those of conventional doxorubicin. However, the use of Peg-Dox in myeloid neoplasms rem...
Na minha lista:
| Publicado no: | Anticancer Drugs |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6749968/ https://ncbi.nlm.nih.gov/pubmed/31283544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000811 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|